Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
108 hedge funds and large institutions have $417M invested in Aerie Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 23 reducing their positions, and 40 closing their positions.
130% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 23
47% more call options, than puts
Call options by funds: $5.52M | Put options by funds: $3.77M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less funds holding
Funds holding: 123 → 108 (-15)
38% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 40
40% less capital invested
Capital invested by funds: $693M → $417M (-$276M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$29.6M |
| 2 |
DM
Deerfield Management
New York
|
+$29.4M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$13M |
| 4 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$13M |
| 5 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$30.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$11.6M |
| 3 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$11.1M |
| 4 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$11M |
| 5 |
HM
HealthCor Management
New York
|
-$11M |
AERI Hedge Fund Activity: Q2 2015 in Review
108 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q2 2015, worth a combined $417M — down 40% from $693M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of AERI and 25 opened new positions — a net loss of 15 holders — while 23 trimmed existing stakes and 53 added.
The largest buyer was PFM Health Sciences, adding an estimated $29.6M. The largest seller was Janus Henderson Investors US, exiting entirely with an estimated $30.3M sold.
- 108 institutional investors held Aerie Pharmaceuticals (AERI) as of Q2 2015, down from 123 in Q1 2015.
- Funds reported $417M of Aerie Pharmaceuticals stock for Q2 2015, down 40% quarter-over-quarter.
- 25 funds opened new Aerie Pharmaceuticals positions in Q2 2015 and 40 closed out, a net change of -15 holders.
- The largest Aerie Pharmaceuticals buyer in Q2 2015 was PFM Health Sciences, an estimated $29.6M added.
- The largest Aerie Pharmaceuticals seller in Q2 2015 was Janus Henderson Investors US, an estimated $30.3M sold.
Based on aggregated 13F filings for Q2 2015.